Clinical evaluation of allogeneic cultured dermal substitutes for intractable skin ulcers after tumor resection

European Journal of Dermatology

Volumn 14, Issue 3, 2004, Pages 172-176

  Moroi, Yoichi ^a   Fujita, Shohei ^a   Fukagawa, Shuji ^a   Mashino, Toshihiko ^a   Goto, Takako ^a   Masuda, Teiichi ^a   Urabe, Kazunori ^a   Kubo, Kentaro ^b   Matsui, Hiromichi ^b   Kagawa, Shizuko ^b   Kuroyanagi, Yoshimitsu ^b   Furue, Masutaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY   (Japan)

Author keywords

Allogeneic cultured dermal substitute; Fibroblast; Full thickness skin ulcer; VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ALLOGRAFT; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; EPITHELIZATION; FEMALE; FULL THICKNESS SKIN GRAFT; GRANULATION TISSUE; HUMAN; MALE; SKIN CANCER; SKIN CULTURE; SKIN INFECTION; SKIN TUMOR; SKIN ULCER; SPLIT THICKNESS SKIN GRAFT; TREATMENT OUTCOME; TUMOR RECURRENCE; WOUND DRESSING;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; SKIN ULCER; SKIN, ARTIFICIAL; TISSUE BANKS; TISSUE ENGINEERING; TRANSPLANTATION, HOMOLOGOUS; WOUND HEALING;

EID: 2942538105     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Rheinwold JG, Green H. Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratomo. Cell 1975; 6: 317-30.
2. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975; 6: 331-43.
3. Green H, Kehinde O, Thomas J. Growth of cultured human epidermal cells into multiple epithelio suitable for grafting. Proc Natl Acad Sci USA 1979; 76: 5665-8.
4. Gallica G, O'Cannor NE, Compton CC et al. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 1984; 311: 448-51.
5. Cooper ML, Honsbrough JF, Spielvogel RL et al. In vivo optimization af a living dermal substitute employing cultured human fibroblasts an a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials 1991; 12: 243-8.
6. Hansbrough JF, Christine D, Hansbrough WB. Clinical trials of a living dermal tissue replacement placed beneath meshed, split-thickness skin grafts on excised burn wounds. J Burn Care Rehabil 1992; 13: 519-29.
7. Hansbrough JF, Coaper ML, Cohen R et al. Evaluation of a biodegradable matrix containing cultured human fibroblasts as a dermal replacement beneath meshed skin grafts on athymic mice. Surgery 1992; 111: 438-46.
8. Gentzkow GD, Iwasaki SD, Hershon KS et al. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care 1996; 19: 350-4.
9. Hansbrough JF, Mozingo DW, Kealey GP et al. Clinical trials af a biosynthetic temporary skin replacement, Dermagraft-Transitional Covering, compared with cryopreserved human cadaver skin for temporary coverage of excised burn wounds. J Burn Care Rehabil 1997; 18: 43-51.
10. Hansbrough JF, Morgan J, Greenleaf G. Development of a temporary living skin replacement composed of human neonatal fibroblasts cultured in Biobrane, a synthetic dressing material. Surgery 1994; 115: 633-44.
11. Bell E, Ivarsson B, Merrill C. Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA 1979; 211: 1274-8.
12. Bell E, Ehrlich HP, Buttle DJ, Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. Science 1981; 211: 1052-4.
13. Bell E, Ehrlich HP, Sher S, Merrill C et al. Development and use of a living skin equivalent. Plast Reconstr Surg 1981; 67: 386-92.
14. Bell E, Sher S, Hull B et al. The reconstitution of living skin. J Invest Dermatol 1983; 81 (Suppl.): S2-10.
15. Naughton G. The Advanced Tissue Sciences story. Sci Am 1999; 280: 84-5.
16. Yamada N, Shioya N, Kuroyanagi Y. Evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix as a wound dressing. Scand J Plast Reconstr Surg 1995; 29: 211-9.
17. Tanaka M, Nakakita N, Kuroyonogi Y. Allogeneic cultured dermal substitute composed of spongy collagen containing fibroblasts: evaluation in animol test. J Biomater Sci Polymer Edn 1999; 10: 433-53.
18. Yamada N, Uchinuma N, Kuroyanagi Y. Clinical evaluation of an allogeneic cultured dermal substitute composed of fibroblasts within a spongy collagen matrix. Scand J Plast Reconstr Surg 1999; 33: 147-54.
19. Kuroyanogi Y, Yamodo N, Yamashito R, Uchinuma E. Tissue-engineered product: allogeneic cultured dermal substitute composed of spongy collagen with fibroblasts. Artificial Organs 2001; 25: 180-6.
20. Kubo K, Kuroyonogi Y. Development of cultured dermal substitute composed of spongy matrix of hyoluronic acid and atelocollogen combined with fibroblasts: fundamental evaluation. J Biomoter Sci Polym Ed 2003; 14: 625-41.
21. Kubo K and Kuroyanagi Y. Characterization of cultured dermal substitute composed of spongy matrix of hyoluronic acid and collagen combined with fibroblosts. J Artif Organs 2003; 6: 138-44.
22. Kuroyana gi Y, Kubo K, Matsui H et al. Establishment af banking system for allogeneic cultured dermal substitute. Artif Organs 2004; 28: 13-21.
23. Culp LA, Murray BA, Rollins BJ. Fibronectin and proteoglycans as determinants of cell-substratum adhesion. J Supramol Struct 1979; 11: 401-27.
24. Lark MW, Laterra J, Culp LA. Close and focal contact adhesions of fibroblasts to a fibronectin-containing matrix. Fed Proc 1985; 44: 394-403.
25. Rollins BJ, Culp LA. Glycosaminoglycons in the substrate adhesion sites of normal and virus-transformed murine cells. Biochemistry 1979; 18: 141-8.
26. Benedetti L, Cortiva R, Berti T et al. Biocampatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomater 1993; 14: 1154-60.
27. Postlethwaite AE, Seyer JM, Kang AH. Chematactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Prac Natl Acad Sci USA 1978; 75: 871-5.
28. Nissen NN, Polverini PJ, Kach AE et al. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. Am J Pathol 1998; 152: 1445-52.
29. Ferrara N, Henzel WJ. Pituitary fallicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-8.
30. Kumar R, Yoneda J, Fidler U. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998; 12: 749-57.
31. Kubo K, Kuroyanagi Y. Effects of vascular endathelial growth factor released from cultured dermal substitute on proliferation of vascular endothelial cells in vitro. J Artif Organs 2003; 6: 267-72.
32. Aragane Y, Okamoto T, Yajima A et al. Hydraxyurea-induced foot ulcer successfully treated with a topical basic fibroblast growth factor product. Br J Dermatol 2003; 148: 599-600.